Pazopanib Hydrochloride CAS 635702-64-6 Maʻemaʻe >99.0% (HPLC) API Hale Hana
Hāʻawi Mea Hana me ka Maʻemaʻe kiʻekiʻe a me ka maikaʻi paʻa
Inoa Kemika: Pazopanib Hydrochloride
CAS: 635702-64-6
ʻO Tyrosine kinase receptor inhibitor no ka mālama ʻana i ka maʻi maʻi maʻi renal cell carcinoma a i ʻole sarcoma ʻili palupalu kiʻekiʻe i loaʻa mua i ka chemotherapy.
API Kūlana Kiʻekiʻe, Hana Hana Kūʻai
Inoa Kimia | ʻO ka Pazopanib Hydrochloride |
Nā huaʻōlelo like | Pazopanib HCl;GW786034 HCl;Votrient;5-[[4-[(2,3-Dimethyl-2H-indazol-6-yl)(methyl)amino]pyrimidin-2-yl]amino]-2-methylbenzenesulfonamide Hydrochloride |
Helu CAS | 635702-64-6 |
Helu CAT | RF-API93 |
Kūlana Kūʻai | Ma ka waihona, ʻoi aku ka nui o ka hana a hiki i nā haneli kilogram |
ʻĀpana Molekala | C21H23N7O2S.ClH |
Kaumaha Molecular | 473.987 |
Ka hikiwawe | DMSO |
Lae hehee | 300.0~304.0 ℃ |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Pauda keokeo a melemele iki |
ʻIkepili | ʻO ke ʻano o ka infraed absorption spectrum o ka laʻana hoʻāʻo e kūlike me ka maʻamau |
Koena ma ka Ignition | ≤0.50% |
ʻO kēlā me kēia haumia kanaka | ≤0.30% |
Huina paumaele | ≤1.50% |
Nā Metala Kaumaha | ≤10ppm |
Maʻemaʻe / Kaʻina Hanana | ≥99.0% (HPLC) |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | API, Tyrosine kinase receptor inhibitor |
Pūʻolo: ʻO ka ʻōmole, ʻeke ʻeke alumini, pahu pahu pahu, 25kg / pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:E mālama i loko o nā pahu i hoʻopaʻa ʻia ma kahi maloʻo a maloʻo;Palekana mai ka malamalama, ka ma'ū a me ka pest infestation.
Pazopanib Hydrochloride (CAS 635702-64-6) he multi-tyrosine kinase inhibitor o vascular endothelial growth factor receptor (VEGFR) -1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR) -α a me - β, fibroblast growth factor receptor (FGFR) -1 a me -3, cytokine receptor (Kit), interleukin-2 receptor-inducible T-cell kinase (Itk), lymphocyte-specific protein tyrosine kinase (Lck), a me ka transmembrane glycoprotein receptor tyrosine kinase (cFms).In vitro, pazopanib inhibited ligand-induced autophosphorylation o VEGFR-2, Kit, a me PDGFR-beta receptors.In vivo, pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation i loko o nā māmāʻiole, angiogenesis i loko o kaʻiole kŘkohu, a me ka ulu ana o kekahi mau xenografts tumo kanaka ma ka iole.Ua ʻae ʻia ia no ka maʻi maʻi maʻi renal cell e ka US Food and Drug Administration ma 2009 a kūʻai ʻia ma lalo o ka inoa kālepa Votrient e ka mea hana lāʻau, ʻo GlaxoSmithKline.ʻO ka Votrient he mea hoʻopaneʻe kinase i hōʻike ʻia no ka mālama ʻana i nā poʻe maʻi me: 1) ka maʻi maʻi maʻi renal cell carcinoma.2) ka maʻi maʻi maʻi maʻemaʻe i loaʻa mua i ka chemotherapy.